Even though there has been a decrease in both infection rates and prevalence of COVID-19 in some parts of the world, in some countries the spread of COVID-19 has not been adequately controlled and the numbers are still rising. Epidemiologists have warned of possible subsequent waves until an effective vaccination becomes available. Until then, recommendations for different aspects of patient care are strictly needed, which underlines the importance of the COVID-19 series of publications in this journal. The recommendations provided in these articles will inform allergists and healthcare providers on the management and treatment of patients during this pandemic. It should be noted that these statements are based on current evidence and medical knowledge and there is a paucity of prospective clinical trials regarding some of the information provided in these documents. These clinical statements need to be regularly updated with incoming new clinical data.
Figure 1. Picture representing the wide range of clinical aspects involved in the pathogenesis of COVID-19.
References
1. Coronavirus disease (COVID-2019) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports, Accessed on 16 Apr 2020.
2. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020.
3. Jesenak M, Banovcin P, Diamant Z. COVID-19, chronic inflammatory respiratory diseases and eosinophils - Observationsfrom reported clinical case series. Allergy. 2020.
4. Zhang M, Guogang X, Fengming D, al. e. The role of peripheral blood eosinophil counts in COVID-19 patients. Allergy. 2020 (in press).
5. Dong X, Cao YY, Lu XX, et al. Eleven faces of coronavirus disease 2019. Allergy. 2020.
6. Zhang JJ, Cao YY, Dong X, et al. Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2. Allergy. 2020.
7. Du H, Dong X, Zhang JJ, et al. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. Allergy. 2020.
8. Sokolowska M, Agache I, Akdis CA. Immune response in Covid-19: mechanisms, clinical outcome, diagnostics and perspectives – an EAACI report. Allergy. 2020 (in press).
9. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy.2020.
10. Gursel M, Gursel I. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?Allergy. 2020.
11. Ozdemir C, Kucuksezer UC, Tamay ZU. Is BCG vaccination affecting the spread and severity of COVID-19? Allergy. 2020.
12. Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020.
13. Cai Q, Huang D, Ou P, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020.
14. Bonini S, Maltese G. COVID-19Clinical trials: quality matters more than quantity. Allergy. 2020.
15. Sotgiu G, Gerli AG, Centanni S, et al. Advanced forecasting of SARS-CoV-2-related deaths in Italy, Germany, Spain, and New York State.Allergy. 2020.
16. Bousquet J, Jutel M, al. ACe. ARIA-EAACI statement on Asthma and COVID-19. Allergy 2020 (submitted). .
17. Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma protective against COVID-19? Allergy. 2020.
18. Johnston SL. Asthma and COVID-19: is asthma a risk factor for severe outcomes? Allergy 2020 (in press).
19. Leonardi A, Fauquert JL, Doan S, et al. Managing ocular allergy in the time of COVID-19. Allergy. 2020.
20. Licari A, Votto M, Brambilla I, et al. Allergy and asthma in children and adolescents during the COVID outbreak: What we know and how we could prevent allergy and asthma flares. Allergy. 2020.
21. Bousquet J, Akdis C, Jutel M, et al. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy. 2020.
22. Klimek L, Jutel M, Akdis C, et al. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement.Allergy. 2020.
23. Pfaar O, Klimek L, Jutel M, et al. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic - an EAACI/ARIA Position Paper. Allergy. 2020.
24. Klimek L, Jutel M, Bousquet J, al. e. Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in the COVID-19 pandemic – An EAACI Position Paper. Allergy 2020 (submitted).
25. Brough HA, Kalayci O, Sediva A, et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics.Pediatr Allergy Immunol. 2020.
26. Untersmayr E, al. e. Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives – a report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020.
27. Gelincik A, Brockow K, Celik GE, et al. Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19.Allergy. 2020.
28. Vultaggio A, Agache I, Akdis CA, et al. Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement. Allergy. 2020.
29. Riggioni C, Comberiati P, Giovannini M, et al. A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy.2020.
30. Allergy homepage. https://onlinelibrary.wiley.com/doi/toc/10.1111/(ISSN)1398-9995.COVID-19. Accessed on 16 Jun 2020.
Disclosure of conflict of interests:
Dr. Pfaar reports grants and/or personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biomay, Circassia, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, MEDA Pharma/MYLAN, Anergis S.A., Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, GSK, Astellas Pharma Global, EUFOREA, ROXALL, NOVARTIS, SANOFI AVENTIS, Med Update Europe GmbH, and streamedup! GmbH. Dr. Torres has no conflict of interest in relation to this work. Dr. Akdis reprots grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kühne-Center for Allergy Research and Education, European Commission’s Horizon’s 2020 Framework Programme, Cure, Novartis Research Institutes, AstraZeneca, SciBase, GSK, and other from Sanofi and Regeneron.